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Paul H. Black, M.D.
Elinor M. Levy, Ph.D.
We have consideredfactors that predispose to infection by the human immunodeficiency
virus as well as the clinical consequences ofinfection. We have also reviewed what is
known about the virological status ofthe asymptomatic carrier, particularly thefemale,
and thefact thatpregnancy may be a cofactorforprogression ofHIVdisease in seroposi-
tive women. Additionally, we have discussed several other cofactors that maypromote the
progression ofHIV infection. These include intercurrent infection, excessive use ofrecrea-
tional drugs and alcohol, malnutrition, and stress. With respect to stress, we have re-
viewed evidence indicating that certain personalityfactors , by buffering the effects of
stress, mayplay a role in determining the outcome ofHIV disease. Possible neuromodula-
tors that may mediate the effect (s) ofstress on the immune system are considered. Also
discussed is the potentially complicating role ofHIV infection ofthe brain ofasymptomat-
ic carriers on psychosocial studies, as well as the possible dysregulation ofneuromodula-
tor levels which might resultfrom such infection. The possibility that HIV infection ofthe
brain may act to enhance progression ofHIV infection is proposed.
One of the major issues concerning AIDS is knowledge of the virological state and
infectivity of the person who has seroconverted to HIV and remains healthy — the
so-called asymptomatic carrier. Equally important is the subject of cofactors — those
factors which may enhance or promote the asymptomatic carrier's progression to AIDS.
In this article, we shall present an overview of these topics and some implications for
seropositive women who become pregnant.
Infection by the Human Immunodeficiency Virus
Upon exposure to HIV, the virus that causes AIDS, a person may develop an acute infec-
tious mononucleosis-like syndrome with or without meningitis. Generally, these infec-
tions subside, an immune response occurs in relationship to the disease, and the patient
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becomes seropositive (Group I, see table l). 1 Other people who are exposed to the virus
may not develop signs or symptoms of illness, and seroconversion may take weeks to
months to occur (Group II, table 1). Little is known about the factors that determine
whether an acute infectious disease occurs or whether a person seroconverts asymptomat-
ically. Moreover, relatively little is known regarding the extent of exposure necessary for
seroconversion. 2 In some studies, 50 to 60 percent of male homosexual partners of in-
fected persons become infected, as judged by antibody testing; 3 approximately the same
figure applies to male-to-female transmission from HIV-infected intravenous drug users
or male bisexuals. 4 Female-to-male transmission appears to be much lower, probably
owing to the lower infectivity by this route. 5 Other studies reveal that four out of eight
women who were artificially inseminated from an infected donor seroconverted, 6 and 50
percent of hemophiliac patients who received a contaminated Factor VIII preparation
seroconverted. 7 Thus it is likely that about half of the people exposed to infectious individ-
uals and materials will seroconvert. Factors such as the amount of virus in the infectious
fluid, route of infection, or host factors, or a combination of these, must certainly be
operative in determining whether seroconversion occurs after exposure to HIV.
Once an individual is infected with HIV and seroconverts, he or she is potentially infec-
tious for the rest of his or her life. We know that the genetic material of the virus (RNA)
is able to make DNA and that this DNA becomes associated with the cell's genes. This
integrated proviral DNA becomes a cellular gene and, as long as the cell lives, will be
a permanent part of its genetic endowment. Approximately 70 to 80 percent of asympto-
matic, seropositive carriers, in whom the infectious virus cannot be found, will have the
latent viral genes activated from their blood cells by various cocultivation and activation
techniques. This finding indicates that most asymptomatic carriers have the capacity to
synthesize the infectious virus but that it is still present in most cells in a latent state. Little
is known as to the actual levels of infectious virus produced by asymptomatic carriers;
however, most evidence suggests that only small amounts of infectious virus are present.
Despite this, a large amount of evidence indicates that a seropositive person, symptomatic
or asymptomatic, is infectious and can transmit the virus. 8
Asymptomatic individuals can transmit the virus by means of genital secretions or
blood or through transmission to the fetus. The virus is certainly in the blood cells in a
latent state. Data are very sparse as to whether the virus in the genital secretions, for
example, the ejaculate of males and the cervical secretions of women, is contained within
cells or is free in bodily fluids in the asymptomatic individual. Some evidence indicates
that the virus resides intracellularly in a latent state in cervical secretions.
9 Transmission
to the fetus by the asymptomatic carrier presumably occurs through the blood, although in
certain unusual circumstances newborns appear to have become infected through nursing. 10
Asymptomatic Female Carrier
Although the virus has been recovered from the cervical secretions of asymptomatic fe-
male carriers by means of cocultivation techniques throughout the menstrual cycle, little
is known about the relative levels of virus in the cervical secretions of women during
various phases of the menstrual cycle or during pregnancy. "
12
Retroviruses in mice can be
activated by certain female sex steroids. 13 This discovery raises a question as to whether
female sex hormones activate virus replication in cells in the cervical secretions which
harbor the virus, such as lymphocytes and macrophages and, if so, which are the activat-
ing hormones. We know very little about these phenomena in humans, but they are impor-
tant, since the type and level of sex steroid vary during different phases of the menstrual
98
Table 1
Summary of Classification System for HIV
Group I. Acute infection
Group II. Asymptomatic infection
Group III. Persistent generalized lymphadenopathy
Group IV. Other disease
Subgroup A. Constitutional disease
Subgroup B. Neurological disease
Subgroup C. Secondary infectious disease
Category C-1 . Specified secondary infectious diseases listed in the CDC
surveillance definition for AIDS
Category C-2. Other specified secondary infectious diseases
Subgroup D. Secondary cancers
Subgroup E. Other conditions
Category C-1 and Subgroup D include those patients whose clinical presentation fulfills
the definition of AIDS used by the Centers for Disease Control for national reporting.
cycle and these factors may be operative in regulating the amount of virus present as well
as its intracellular or extracellular location in urogenital secretions. This possibility is of
obvious importance with respect to heterosexual transmission, since it is the infectious
virus in cervical secretions which passes from the female to the male and transmits the
disease. Many of these questions can be addressed by utilization of various techniques that
have been shown to activate or stimulate virus production in vitro. For example, one could
treat infected lymphocytes or macrophages, or both, with various sex steroids and meas-
ure the production of infectious HIV.
Pregnancy and the Asymptomatic Female Carrier
Of the fetuses born from women who are infected with HIV prior to pregnancy, approxi-
mately 50 percent are infected with HIV. For subsequent pregnancies, the percentage is
even higher. Current evidence indicates that virus is generally passed from mother to
fetus during the intrauterine residence of the fetus rather than perinatally. 14 This evidence
stems from the fact that Caesarean section does not protect the fetus from infection. 15
Moreover, the virus can be recovered from the fetal compartment in cases of elective
Caesarean section at twenty and thirty-six weeks. 16 Thus, most evidence indicates that the
virus passes from mother to fetus transplacentally. There are reported cases, however, in
which virus has been passed to the neonate via the milk. 17
That pregnant positive women may pass the virus to the fetus in approximately 50 per-
cent of pregnancies and that pregnancy may influence the course and progression of the
disease in infected women raise many issues regarding testing for HIV positivity and
counseling women who are found to be seropositive.
One important question concerns the progression of disease during pregnancy. Does
pregnancy enhance the progression of disease in a healthy female carrier? There is evi-
dence at present to suggest that HIV-infected women who have already given birth to an
infected child have an increased risk of developing AIDS during the subsequent preg-
nancy or soon thereafter. 18 It is possible that exposure to paternal antigens of the fetus
triggers an immune response that is likely to activate latently infected immune cells. Viral
replication is more likely to take place in such stimulated cells. It has been suggested that
these events have a cumulative effect, since the risk of AIDS does not seem to increase in
the first pregnancy of an HIV-infected woman in some studies. 19 In still other studies,
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progression was evident in women during the first pregnancy. 20 Obviously, studies must
be carried out to resolve this important issue, but it seems clear that pregnancy can be a
cofactor for progression, which poses the question as to whether such progression is due
to enhanced viral activation or to the immunosuppressed state that accompanies preg-
nancy. This subject will be discussed below.
Infection ofthe Brain
At what point the brain, which is affected in 85 to 95 percent of AIDS cases, is seeded
with virus is not known at the present time. 21 It is entirely possible that the brain may be
seeded with virus at the time of initial infection. This is what occurs with visna, a disease
in sheep caused by a subgroup of retroviruses, the lentiviruses, a group to which HIV
belongs. In visna infection, the virus is brought to the brain in a monocyte; presumably
this happens with HIV infection, since the virus infects monocytes, and monocytes are the
cells most frequently infected in the brains of AIDS patients. These monocytes may ap-
pear as multinucleated, syncytial giant cells, and viral replication has been documented in
these cells. Evidence indicates that the brain is seeded with HIV in healthy, asymptomatic,
seropositive individuals. 22 These conclusions are based on studies carried out with the
cerebrospinal fluid (CSF). If antibody to a virus is present in the CSF, it is extremely
likely that virus is replicating in the brain. In most chronic virus infections of the brain,
such as measles and visna, replication of virus in the brain evokes antibody production in
the brain, and the antibody subsequently appears in the CSF. Other tests can be carried
out to detect viral antigen in the CSF, which is also indicative of brain infection. That the
brain is seeded by the virus, possibly very early, is important, since the brain may act as a
reservoir for virus replication. The brain frequently harbors chronic, subacute, and latent
virus infections. Why various virus infections persist in the brain is not known. It is
known that the brain is an immunologically privileged site, probably owing, in no small
part, to the blood brain barrier and the lack of lymphatic supply to the brain. The fact that
HIV persists in the brain will make eradication of the infection very difficult indeed,
since most drugs pass the blood brain barrier poorly, if at all.
In the preceding sections, we have considered the likelihood of becoming infected with
HIV as well as the consequences of infection with respect to the development of acute
disease or seroconversion without clinical disease. We have also considered the viral
status and infectivity of the asymptomatic carrier, particularly the woman. Pregnancy as a
factor promoting progression of disease and the possible mechanisms implicated in ma-
ternal to fetal spread were also discussed. The likelihood of invasion of the central ner-
vous system by CNS HIV was considered. The HIV carrier may feel completely well for
many years, or he or she may experience progression of the disease. We will now consider
the factor(s) that may influence the outcome of HIV infection.
Progression to AIDS
In table 1 , a summary of the new Centers for Disease Control (CDC) classification system
for HIV is presented. We define progression as the development of disease in asymptomat-
ic individuals (Group II), which may be minor (persistent generalized lymphadenopathy
[PGL], Group III) or severe (Group IV). It should be noted that in the CDC classification,
several distinct symptomatic presentations of HIV infection are now included. Within
Subgroup A of Group IV, for example, fall cases formerly termed AIDS-related complex,
or ARC.
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What, then, is the likelihood of progression? Various studies indicate that at least 50
percent of seropositive individuals will experience progression of HIV infection to a dis-
ease included in Group IV. The likelihood that progression will occur is strongly related
to the length of the HIV infection. 23 Several studies suggest that the incidence of progres-
sion of persons in Group III, or PGL, is similar to that of persons in Group II. 24 What
percentage of asymptomatic carriers will remain so, without progression clinically or
immunologically, is not known for certain. These individuals must, of course, be followed
for longer periods.
The question of whether the persistently asymptomatic state reflects containment of the
replication of HIV by means of certain unspecified factors or through specific immune
mechanisms, or both, remains unanswered. Although it is not known for certain, it is
likely that a slower rate of progression in some individuals reflects a relative lack of co-
factors; put another way, it is likely that cofactors enhance progression. We postulate that
the cofactors act by increasing viral replication or by altering the capacity of the immune
system to contain the infection, or by doing both. This proposed mechanism of progres-
sion is untested at present and likely will remain so for years. Nevertheless, we would
assume that anything that activates viral replication or that diminishes the immune re-
sponse would favor progression.
The likelihood that cofactors influence the development of AIDS is of paramount im-
portance. We have already pointed out that pregnancy may increase the risk of developing
AIDS in an asymptomatic carrier. There is much current feeling that other cofactors such
as intercurrent infection, malnutrition, excessive use of recreational drugs and alcohol,
and stress may all play a role in the development of disease in people infected with the
HIV agent. We will discuss these factors after briefly reviewing the question of genetic
predisposition.
Genetic Influence
Susceptibility to HIV infection as well as rates of disease progression may depend on
genetic characteristics, for example, a predisposition for acquisition of the disease; the
evidence for this, however, is very preliminary. Some data have been presented linking
HIV infection with a certain genetic phenotype (group specific component [Gc]) in homo-
sexual men. 25 Yet, in a series of seropositive hemophiliac patients, no significant differ-
ence was found between patient and control populations with respect to this genetic
marker. 26
Other studies, mainly from New York, indicate that the HLA-DR5 antigen is positively
associated with Kaposi's sarcoma as a manifestation of AIDS. 27 The significance of these
preliminary studies is unknown, and more studies must be done. However, the notion that
there may be a genetic influence on susceptibility to, or progression of, HIV infection
remains a fascinating one.
Intercurrent Infection
A large body of evidence indicates that replication of HIV may occur only in an activated
cell. The infectious viral cycle generally does not proceed to virus production, but pro-
ceeds only to proviral DNA synthesis and integration in a resting lymphocyte. Upon
lymphocyte activation, viral replication occurs and progeny virus is produced. 28 In a la-
tently infected cell as well, virus synthesis may occur only after cell activation with vary-
ing agents that stimulate lymphocytes to divide, such as various antigens or infectious
agents. 29 Elegant molecular biological studies have identified a factor produced by acti-
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vated T-cells, a subset of lymphocytes, which enhances the expression and replication of
HIV. 30 This factor is a protein that binds to the regions of the viral genome which enhance
the expression of viral genes. Such studies indicate that stimulation of lymphocytes asso-
ciated with another infection can activate HIV virus replication both during an acute in-
fection and in a latently infected cell.
Infectious processes, by activating HIV replication, may promote the infection of a
greater number of target cells and cause their ultimate destruction. Through this amplifi-
cation, the threshold for clinical disease might then be reached. Tuberculosis and general-
ized viral infections have been thought to act as cofactors for HIV progression in this
way. 31 There is, however, much more evidence that intercurrent sexually transmitted in-
fections such as gonorrhea, syphilis, primary herpes simplex, hepatitis B, and nonspecific
urethritis acquired after HIV infection are strongly associated with the development of
symptomatic disease in two separate cohort studies. 32 33 It has been suggested that inter-
current sexually transmitted disease may also act to promote seroconversion in the follow-
ing way: 34 HIV may have infected relatively few T-lymphocytes and/or macrophages (the
cells of the immune system most susceptible to HIV infection) at the site of entry of the
virus, and thus may not have provided sufficient viral antigens to illicit an immune re-
sponse. Such latently infected cells, when activated as part of a local, or systemic, re-
sponse to infection, may then release sufficient viral particles to induce a primary
specific immune response. Pinching further speculates that this phase of required HIV
replication may explain the relatively long latency period between exposure and serocon-
version (generally six weeks to three months; however, lag periods of up to twelve months
have been reported), longer than with most other infections or immunizations. 35 One
would want to have more data as to how often seroconversion is triggered by intercurrent
infections, although this information might be difficult to obtain. Whether or not this
hypothesis can be substantiated, the epidemiological evidence of the association of inter-
current infection and progression of HIV disease suggests that intercurrent infections are
an important cofactor. Moreover, other studies indicate that the presence of lesions in the
genital area which are associated with sexually transmitted diseases may be a risk factor
for HIV infection, since such lesions may provide a portal of entry for the virus. 36
Malnutrition
Many studies have indicated that severe protein calorie malnutrition and a variety of single
nutrient deficiencies are causes of defective-cell-mediated immunity and of other defec-
tive immune functions. 37 Stated another way, deficiencies in calories in general as well as
specific vitamins or minerals can lead to deficiencies in immune function. Malnutrition as
a result of persistent diarrhea and malabsorption may contribute to further impairment of
immunity and the progression of AIDS. Some evidence indicates that nutritional status
decreases as the severity of HIV-related illness increases from an asymptomatic seroposi-
tive state to AIDS. 38 It is likely that malnutrition plays an important role in the progression
of HIV infections in central Africa.
Recreational Drugs and Alcohol
The excessive use of alcohol or recreational drugs, or both, can cause immunosuppres-
sion.
39 w The contribution of alcohol and drug use to HIV-related disease is uncertain at
this time, however, as recent studies were unable to demonstrate that the use of these sub-
stances contributes significantly to disease progression. 41 42 Chronic use of alcohol, which
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may result in cirrhosis of the liver and diminished host resistance, could certainly act as a
cofactor for disease progression.
Stress
A growing literature suggests that mental attitudes and emotions may influence the pro-
gression of infectious diseases, including those associated with HIV. Such studies, to-
gether with those dealing with psychosocial aspects as predictors of which infected
individuals will progress to AIDS, are attempting to determine the relationship between
mental processes and the immune system. This is a new field of study, which has been
called psychoneuroimmunology. 43 Such studies are extremely important, since they may
reveal mechanisms that will aid in determining whether and how stress and associated
dysphoria may be cofactors in the progression ofHIV infection to AIDS.
If distress is such a cofactor, it becomes important to determine the personality factors
and interventions that may be instrumental in buffering the effects of stress. A number of
reports have indicated that hardiness is associated with less illness in highly stressed indi-
viduals. 44 Hardy individuals are defined as those who make commitments, welcome chal-
lenge and change, and tend to feel that they can exercise control over their lives. Psycho-
logical tests to measure hardiness have found that men who are "most hardy" on the
control subscale have a greater longevity following diagnosis of Pneumocystis carinii
pneumonia. 45
Another study has indicated that patients with Kaposi's sarcoma who are following a
macrobiotic regimen have survived with their disease for as long as three to five years. 46
These patients have shown some improvement in their immunologic profile without medi-
cal therapy. Survival patterns such as these in patients with Kaposi's sarcoma are not
frequently encountered. As the choice to practice a macrobiotic way of life and the ability
to continue with it involve many changes and require a strong commitment, one would
predict that the individuals in the study are quite hardy. In addition, an important compo-
nent of the practice of a macrobiotic regimen is the belief that health can be controlled by
diet. This belief presumably reduces the sense of hopelessness associated with AIDS. In
animal studies, helplessness and hopelessness are associated with immune suppression.
The extent to which the clinical improvement is due to the macrobiotic diet per se or the
psychological involvement in the macrobiotic way of life or the particular "mind set" of
those who choose an alternative therapy is not completely understood at present.
The aforementioned studies suggest that certain personality characteristics indicative of
"psychological health" and a feeling of involvement and commitment may influence the
course of HIV infection. It would not seem unlikely that stress and dysphoria influence
progression of disease in HIV-infected persons. Numerous studies have revealed that the
immune function can be diminished by many of the chemicals released from the brain or
nerves, which are called neuromediators, neurohormones, and neurotransmitters and
which mediate the effects of stress. 47 Furthermore, the psychological depression experi-
enced by many people who have seroconverted to HIV may itselfbe immunosuppres-
sive.
48 Although it is likely that any progression of HIV infection which is caused by stress
is brought on by the immunosuppressive effect(s) associated with stress, it is also possible
that the virus is directly activated in cells by certain of the neuromediators just referred to.
HIV production is, for example, stimulated by corticosteroids. Activation of other viruses
by several of these substances has been demonstrated in animal cells in vitro as well as in
vivo. 49 In humans, certain neurohormones can also activate viruses; for example, epineph-
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rine can activate latent herpes simplex virus infection in the rabbit eye. 50
The effect(s) that the mind has on the HIV disease process are complicated by the possi-
bility of the presence of HIV in the brain of asymptomatic carriers. As we have men-
tioned, the time when the brain is seeded with HIV is not known. It is evident that central
nervous system seeding occurs eventually in most patients who progress, since the vast
majority (85 to 95 percent) of patients with AIDS have pathological evidence of AIDS
encephalopathy at autopsy. 51 Indeed, evidence indicates that of those diagnosed with
AIDS, 20 percent may initially present with a psychiatric or neurological syndrome.
Therefore, psychological or psychosocial studies on asymptomatic carriers may be com-
plicated by the presence of HIV in the brain of an asymptomatic carrier. It is known, how-
ever, that the brain may contain HIV without psychiatric or neurological signs or
symptomatology. 52 Thus, infection of the CNS may remain asymptomatic. One can deter-
mine whether the brain is seeded with HIV by examination of the CSF for HIV antigen or
antibody to HIV (see above), but performance of such studies may be difficult to justify
because of the risk associated with spinal tap. Recently, neuropsychological testing has
been developed to identify subjects with "likely early" or "early" AIDS-related demen-
tia.
53 This finding should allow researchers in this area to analyze their data for a possible
confounding effect of organically induced alterations in mood and personality.
Although few studies have been carried out so far, it is possible that production and
levels of neurotransmitter substances are altered in an HIV-infected individual who has
seeded the brain. At present, there is no evidence that neurons are infected by HIV. How-
ever, the cells in the brain known to be infected by HIV (monocytes, endothelial cells, and
certain glial cells) 54 elaborate substances that have been shown to affect certain neuro-
transmitter substances in neurons. 55 Similarly, monocytes and T-lymphocytes can also
secrete factors that influence brain function. Altered neurotransmitter substances in the
CNS may, in turn, affect immune function. 56 Thus, a complex interaction exists whereby
products of cells of the immune system or other cells capable of secreting similar products
influence the levels of neuromediators in the brain. 57 Whether HIV infection alters the
function ofCNS cells with respect to production of, or response to, neurotransmitter or
immunomodulatory substances, respectively, is currently unknown. We speculate that
because of these alterations, progression may occur more rapidly in an asymptomatic
person who has HIV infection of the brain. Much work must be done to delineate further
the relationship between the central nervous and immune systems, the ways in which
emotions affect the immune system, and whether and how HIV infection in general, and
of the brain in particular, alters these interactions. Such studies may help determine
whether and how stress may be a cofactor in either the development or the progression of
AIDS.
Summary
We have attempted to present an overview of the factors that may play a role in determin-
ing whether progression occurs in the HIV-positive asymptomatic person. Pregnancy,
intercurrent infection, malnutrition, excessive use of recreational drugs and alcohol, and
stress, as well as certain genetic factors, may influence the progression of disease. It will
be important to determine whether progression occurs more rapidly in a seropositive
individual with CNS infection by HIV.
Although our knowledge about the factors predisposing to the progression of HIV in-
fection is not extensive, it is extremely likely that cofactors play an important, if not a
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determining, role. Thus, modifying behavior could presumably influence the outcome of
an HIV infection. Present data suggest that by avoiding the use of recreational drugs and
alcohol, and reducing stress or buffering its effects, one would be maximizing the host
potential to combat infection. Since there is no cure for HIV infection at present, a better
understanding of the psychological, biological, and behaviorial influences that act as
cofactors is of great importance. Research is urgently needed in these areas, so that accu-
rate information can be used as a basis for devising more effective treatment strategies,
setting public policy, and educating persons at risk. More specific knowledge could thus
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Glossary continuedfrom page 96
Provirus. This is DNA made from an RNA template (of an RNA
virus) by the enzyme reverse transcriptase, and it is re-
quired for replication of the virus. This DNA becomes
permanently associated with the DNA of the cell and, as
long as the cell lives, will remain associated with the cell's
genes.
Seroconversion. The development of antibody to an infectious agent is
termed seroconversion. This occurs during acute infectious
diseases. It may also occur without obvious clinical disease
or symptoms. In the latter case, the seroconversion may be
termed silent or asymptomatic. Most infections and sero-
conversions with HIV are of the asymptomatic variety.
T-lymphocytes. Lymphocytes are a class of white blood cells responsible for
specific immunity. T-lymphocytes are a subclass of lympho-
cytes and include cells that can kill virally infected cells.
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"I have no immune system. You people are much more likely to
give me something than lam ever likely to give you something.
And I don V think very manypeople think in those terms, that
we 're the ones at risk. Just being in a room, people coughing
and sneezing, couldput me in the hospital, and you have
virtually nothing tofearfrom me, so I mean, that reversal of
roles has to be brought home.
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A loss of the power of muscular coordination.
A disorder of the autonomic nervous system which mani-
fests in abnormalities of functions governed by the auto-
nomic nervous system, such as temperature regulation and
maintenance of blood pressure.
Computerized axial tomography, a special radiographic
examination consisting of a series of x-rays.
A shrinkage of the outer tissues of the brain (known as the
cortex of the brain).
The science or study dealing with the cytologic and histo-
logic structure of abnormal or diseased tissue.
A condition in which the deep tendon reflexes are exagger-
ated.
A medication that acts as a stimulant on the central nervous
system.
An antipsychotic medication.
Diffuse disease of the brain.
A diminished state of alertness.
A form of low blood pressure which occurs when the sub-
ject stands.
Inflammation of the brain which progresses at a moderate
rate.
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